BFM
ACOR

Boothbay Fund Management’s Acorda Therapeutics ACOR Stock Holding History

Boothbay Fund Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,058
Closed -$504K – 1138
2019
Q4 		$504K Buy
+2,058
New +$519K 0.04% 485

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boothbay Fund Management's ACOR Position: Q1 2020 in Review

Boothbay Fund Management sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 2,058 shares — an estimated $504K sold.

Boothbay Fund Management first reported a position in ACOR in Q4 2019 and held it in 1 quarter. The position peaked at $504K in Q4 2019. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

  • Boothbay Fund Management reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 2,058 Acorda Therapeutics shares in Q1 2020, an estimated $504K.
  • Boothbay Fund Management first reported a position in Acorda Therapeutics in Q4 2019 and held it in 1 quarter.
  • Boothbay Fund Management's Acorda Therapeutics position peaked at $504K in Q4 2019.
  • 106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on Boothbay Fund Management's 13F filing for Q1 2020, filed 15 May 2020.